What is Amylyx Pharmaceuticals Inc?
, a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.37B.
A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 19361,302 shares $11.0M | 0 |
| 3-6months | 115,000 shares $264k | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |